Could a common diabetes drug boost immunotherapy in Hard-to-Treat cancers?
Disease control
Not yet recruiting
This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…
Phase: PHASE1 • Sponsor: Fernando Maciel Barbosa • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC